Skip to main content
. 2022 Apr 30;15(5):558. doi: 10.3390/ph15050558

Figure 7.

Figure 7

Apt–cL–triGemcitabine conjugate treatment selectively inhibits TNBC cell proliferation with few side effects on off-target cells. Cultured MDA-MB-231 (TNBC) cells (A) and T47D (non-TNBC) cells (B) were treated with Apt–cL–triGemcitabine conjugate or free drug at equimolar amounts of gemcitabine as indicated. Resultant changes in cell proliferation rates (%) were kinetically measured using a CCK-8 cell proliferation assay kit at day 1, 2, and 3 post treatment. Untreated cells were used as a background baseline control. Significant differences between groups are indicated with asterisks. p ≤ 0.05 was considered significant. **: p ≤ 0.01; ***: p ≤ 0.001 (Student’s t-test).